Letters New infertility treatments

Role of the private sector in developing new infertility treatments

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f6623 (Published 06 November 2013) Cite this as: BMJ 2013;347:f6623
  1. Marco Gaudoin, medical director1,
  2. Richard Fleming, scientific director1,
  3. Paul Mitchell, embryologist and managing director1
  1. 1GCRM, Glasgow G51 4FD, UK
  1. marco.gaudoin{at}gcrm.co.uk

Hurley’s article on new technologies in infertility treatment requires a response.1 In more than 30 years of in vitro fertilisation, assessment of embryo quality has changed little. It is based on subjective assessment consisting of two or three examinations over 2-5 days, during which embryos are removed from their controlled environment. The “best” embryo is not always selected, …

View Full Text

Log in

Log in through your institution


* For online subscription